Biotech entity
Jane Street Group LLC is most often covered alongside Wall Street Zen, which appears in 2 of these 2 stories. Source depth averages 2 original sources per story, versus 2.2 across the same-window beat baseline. Their average consequence score of 5 runs below the beat's 5.5 for that window.
Last mentioned: Aug 17, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Jane Street Group LLC is most often covered alongside Wall Street Zen, which appears in 2 of these 2 stories. Source depth averages 2 original sources per story, versus 2.2 across the same-window beat baseline. Their average consequence score of 5 runs below the beat's 5.5 for that window. Coverage clusters in funding, which accounts for 1 of those 2, with the remainder spread across 1 other category. We currently track 2 Biotech stories that mention Jane Street Group LLC, published between August 13, 2026 and August 17, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 22 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Jane Street Group LLC. Shared-story counts are live from our verified record — not editorial picks.
Q2 earnings released; EPS beats consensus
Company reported ($1.40) EPS versus ($1.55) consensus; shares rose $0.05 to $0.57 on 2.3x average volume
Weiss Ratings reiterates Sell
Restated a 'sell (e+)' rating on MBRX shares in a research note
Wall Street Zen downgrades MBRX
Cut its rating from 'sell' to 'strong sell' in a research note
Jane Street Group discloses new MBRX position
Acquired 22,550 shares valued at approximately $75,000 during Q4 2025, per SEC filing, representing about 1.11% of the company
Clinical-stage Moleculin Biotech is now valued at just $4.06 million after a 97% collapse from its 52-week high, raising existential questions about its ability to fund development of therapies for resistant tumors and viral infections. The EPS 'beat' of ($1.40) versus ($1.55) is a paper figure — no revenue, cash balance, or clinical milestone accompanied the report.
Source: dailypolitical.com · themarketsdaily.com
SCYNEXIS shorts collapsed 87.6% to 320,181 shares, signaling bear exhaustion, while Ensysce Biosciences short interest exploded 619.9% to 364,278. Focus Universal also saw a 282.8% build, reflecting a stark divergence in microcap biotech sentiment.
Source: tickerreport.com · dailypolitical.com
Jane Street Group LLC is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
